Purpose: This prospective, nonrandomized study evaluates 4 schedules of granulocyte colony-stimulating factor (G-CSF) for patients with breast cancer receiving adjuvant dose-dense chemotherapy regarding febrile neutropenia, treatment delays, and costs.
A djuvant chemotherapy for patients with early-stage breast cancer has been shown to improve both disease-free survival and overall survival. 1 The Cancer and Leukemia Group B (CALGB) 9741 trial compared a conventional schedule of 4 cycles of doxorubicin and cyclophosphamide followed by 4 cycles of paclitaxel every 3 weeks with an accelerated, dose-dense schedule of the same chemotherapy given every 2 weeks. Results showed that the dose-dense schedule improved disease-free survival (risk ratio=0.74; P=0.010) and overall survival (risk ratio=0.69; P=0.013) among women with lymph node-positive breast cancer. 2 Neutropenia is a major cause of morbidity and mortality in patients receiving various schedules of chemotherapy, leading to a decrease in the dose of cytotoxic agents and delay in the interval between cycles, and limiting the dose intensity of the treatment. Recombinant human granulocyte colony-stimulating factor (G-CSF, filgrastim) increases the white blood cell count, decreases the duration of neutropenia, reduces the incidence of febrile neutropenia and the length of hospitalization, and helps to prevent delays in the interval between treatment cycles, preserving dose intensity and density. [3] [4] [5] [6] [7] In the CALGB 9741 study, filgrastim given consecutively from days 3 to 10 of each cycle of the dose-dense schedule allowed the regimen to be delivered safely and resulted in a reduction in the rate of neutropenia and febrile neutropenia compared with the conventional schedule. Grade 4 neutropenia and febrile neutropenia were more frequent in the 3-week regimens (33%, 6%) than in the dose-dense regimens (6%, 2%). 2 Pegfilgrastim, a pegylated version of filgrastim, has a longer median serum half-life (42 h) than filgrastim (3.5 h) allowing less frequent growth factor administration. Data from studies of both normal volunteers and cancer patients showed prolonged serum levels of cytokine, with self-regulation of pegfilgrastim levels as a function of the neutrophil count, allowing less frequent dosing and maintaining stable levels of neutrophils. [8] [9] [10] [11] Randomized trials have shown equivalent myeloid support for both pegfilgrastim, administered every 3 weeks, and filgrastim given to patients receiving intensive adjuvant chemotherapy. [11] [12] [13] A recent phase 2 trial indicated that pegfilgrastim was effective and safe in patients with breast cancer receiving dose-dense chemotherapy, minimizing rates of febrile neutropenia (1.5%). 14 Although pegfilgastrim was well tolerated, hyperleukocytosis has been observed, raising concerns ''about the potential overutilization of pegfilgrastim in some patients.'' 15 It has been suggested that switching from pegfilgrastim to just a few doses of filgrastim might be enough to adequately support adjuvant chemotherapy. Compared with daily filgrastim administration for 7 days (days 8 to 14), fewer doses of 2 (days 8 and 12) and 4 (days 8, 10, 12, and 14) alternating days showed less bone pain and incidence of fever. 16 In addition, it was found that anemia tended to progressively worsen during chemotherapy with increasing length of G-CSF administration, and that the hemoglobin decrease was minimal with a shortened filgrastim schedule. 16, 17 Considering the potential clinical and financial implications for this relatively costly drug, it seems worthwhile to determine whether shorter courses of filgrastim may be sufficient for the prophylaxis of neutropenia in the adjuvant dose-dense chemotherapy treatment of patients with breast cancer.
At our institution, since the introduction of the dose-dense regimen for adjuvant treatment of patients with high-risk breast cancer, granulocyte growth factor support has been delivered for either 8 or 5 days (days 3 to 10 or days 3 to 7), 4 times every other day (days 5, 7, 9, and 11), or by 1 single dose of pegfilgrastim on day 2, based upon the physician's predilection. The primary objective of our study was to evaluate the 4 different schedules of growth factor support administration with regard to the occurrence of febrile neutropenia, hospitalization events, treatment delays, and other hematological toxicities. A secondary objective was to assess the direct growth factor cost in the 4 treatment schedules.
PATIENTS AND METHODS
The study was a prospective, nonrandomized trial of 4 different granulocyte growth factor support schedules in highrisk patients with breast cancer receiving dose-dense adjuvant chemotherapy. All consecutive patients treated between June 2003 and January 2009 were evaluated. Eligible patients were women or men after primary surgical treatment for invasive breast cancer stages I to III, performance statuses 0 to 1, with adequate organ function, defined as normal blood counts, normal liver and renal function, left ventricular ejection fraction greater than or equal to 50%, and without serious concomitant diseases or other primary malignancies. The chemotherapy regimen was a modified schedule of the dosedense arm 4 of the CALGB 9741 trial, delivering 4 cycles of doxorubicin (60 mg/m 2 ) and cyclophosphamide (600 mg/m 2 ) (AC) once every 2 weeks for 4 cycles, followed by weekly paclitaxel (80 mg/m 2 ) for 12 weeks. Although there is no direct comparison between the original CALGB 9741 of paclitaxel (175 mg/m 2 ) given once every 2 weeks for 4 cycles to weekly paclitaxel for 12 weeks, we preferred this regimen according to its better hematological toxicity profile and similar effectiveness compared with paclitaxel given once every 3 weeks. 18, 19 Patients with Her2-neu-positive tumors received adjuvant trastuzumab concomitant with paclitaxel and afterward, for a total of 1 year.
Four different schedules of granulocyte growth factor support were allowed at the discretion of the primary physician during the 4 AC cycles: 8 consecutive days of subcutaneous filgrastim, 300 mcg/d, from days 3 to 10, as given in the original CALGB study (group A), 5 consecutive days of the same dose of filgrastim from days 3 to 7 (group B), 4 times every other day (same dose on days 5, 7, 9, and 11, group C), or 1 single dose of pegfilgrastim, 6 mg, on day 2 (group D). Granulocyte growth factor support was not given during the weekly paclitaxel phase. A complete blood count was obtained at baseline and on day 1 of each AC cycle and weekly paclitaxel. Complete blood counts were obtained between cycles only in patients who were hospitalized for febrile neutropenia. Prophylactic antibiotics were not given. Treatment delays or dose reductions were decided by the primary physician according to departmental guidelines based upon the grade of hematological and nonhematological toxicities. Comparison of treatment toxicities was made for white blood cell and neutrophils counts, hemoglobin level and platelet counts, and episodes of febrile neutropenia, hospitalization events, and treatment delays after each AC cycle and the first week of paclitaxel within and among the 4 G-CSF schedules. Febrile neutropenia episodes were defined for neutrophils count lower or equal to 0.5Â 10 9 /L associated with temperature over 381C measured twice over a 1-hour period or 1 measurement over 38.51C. All patients were admitted to our hospital and quality control was ensured so that the admission matched the criteria required for febrile neutropenia diagnosis. Costs were evaluated for each treatment arm according to average international rates. The study was approved by the Institutional Review Board.
Statistical Analysis
All statistical analyses were post hoc and initially carried out for the 4 groups (A, B, C, and D) as follows: 8 consecutive days of subcutaneous filgrastim, 300 mcg/d, from days 3 to 10, as given in the original CALGB study (group A); 5 consecutive days of the same dose of filgrastim from days 3 to 7 (group B); 4 times of the same dose of filgrastim every other day on days 5, 7, 9, and 11 (group C); or 1 single dose of pegfilgrastim, 6 mg, on day 2 (group D). Later, the following combinations of groups were compared: groups A and D versus groups B and C, and groups A, B, and D versus group C. In addition, each of the groups A, B, and D was compared separately with group C. The analyses were carried out for all new group combinations (A and D, B, E, and C, and A, B, and D). We compared the baseline characteristics using t test and the 1-way analysis of variance for numerical measurements, and the w 2 test and the Fisher exact test for categorical measurements. Numerical data are expressed with the mean±standard deviation, and categorical data with percentages.
The analysis of variance test, with repeated measurements and the paired t test were used to examine the changes in the behavior of measurements such as white blood cells, platelets, and hemoglobin over time.
The Logistic Regression model was used to investigate factors affecting the occurrence of treatment delays (yes/no delay) and febrile neutropenia (yes/no event).
For all the analyses, we used 5% significance level as the cutoff point. All the analyses were carried out using SPSS 14.0.1 (SPSS Inc, Chicago, IL).
RESULTS
A total of 231 (229 females) consecutive patients, aged 26 to 73 years (median 52 y), were evaluated. The patients' characteristics and the pathological features of their tumors are listed in Tables 1 and 2 , respectively. Eighty-four patients (36.4%) received subcutaneous filgrastim (300 mcg) consecutively from days 3 to 10 (group A); 26 patients (11.3%) received the same dose of filgrastim consecutively from days 3 to 7 (group B); 64 patients (27.7%) received filgrastim 4 times every other day on days 5, 7, 9, and 11 (group C) and 57 patients (24.6%) received a single dose of pegfilgrastim, 6 mg, on day 2 (group D). Overall, 141 patients (61.0%) were included in groups A and D (long-term G-CSF) and 90 patients (39.0%) were included in groups B and C (short-term G-CSF). The incidence of febrile neutropenia in each group is listed in Table 3 . Thirteen patients (5.6%) were hospitalized due to 14 episodes of febrile neutropenia: 3 patients in group A (3.6%), 3 patients in group B (11.5%), 1 patient in group C (1.5%), and 6 patients (10.5%) in group D. One of the episodes of febrile neutropenia occurred during cycle 1 in groups A and C (group D), 3 occurred during cycle 2 (2 in group B and 1 in group D), 5 during cycle 3 (2 in group A and 3 in group D), and 5 during cycle 4 in groups A and C (2 in group A, 1 in group B, 1 in group C, and 1 in group D). The characteristics of the patients who developed febrile neutropenia---body surface area, body mass index, and concomitant diseases are listed in Table 4 . Overall, 7 of the 174 patients who received filgrastim developed 8 episodes of febrile neutropenia (4.5%) and 6 of the 57 patients who received pegfilgrastim developed 6 episodes of febrile neutropenia (10.5%). No statistically significant difference was observed among the 4 groups (P = 0.267) or in a comparison of the incidence of febrile neutropenia in groups A and D (long-term G-CSF) versus groups B and C (short-term G-CSF, P = 0.378) or groups A, B, and D versus group C (shortest-term G-CSF, P = 0.082). We also compared the incidence of febrile neutropenia separately for each treatment group versus group C (G-CSF on days 5, 7, 9, and 11). A statistically significant difference was found between group D (pegfilgrastim) and group C (P = 0.041). All 14 episodes of febrile neutropenia required hospitalization and intravenous antibiotic treatment with a median duration of hospitalization of 3 days (range, 1 to 7 d). Thirty-five of the 924 cycles (3.8%) were delayed between 3 to 7 days: 17 cycles in group A (5.0%), 1 in group B (0.9%), 10 in group C (3.9%), and 7 in group D (3.0%). The treatment delays in all the groups were due to febrile neutropenia events and nonhematological toxicity. No statistically significant difference was found among the 4 treatment groups or between groups A and D (long-term G-CSF) and groups B and C (short-term G-CSF). The overall dose intensity for groups A and C was 96.2%. There were no statistically significant differences in white blood cell, neutrophil, or platelet counts in any cycle between or within the different arms. The mean white blood cell counts Group A: G-CSF 300 mcg days 3 to 10; group B: G-CSF 300 mcg days 3 to 7; group C: G-CSF 300 mcg days 5, 7, 9, and 11; group D: pegfilgrastim 6 mg day 2. ER indicates estrogen receptor; G-CSF, granulocyte colony-stimulating factor; IDC, infiltrating duct carcinoma; ILC, infiltrating lobular carcinoma; PR, progesterone receptor. on day 1 of each cycle ranged from 7.8 to 8.7 K/mcL, the mean neutrophil counts ranged from 4.8 to 6.3 K/mcL, and the mean platelet counts ranged from 229 to 275 K/mcL. Hemoglobin levels progressively decreased after each cycle of AC compared with the initial values, ranging from a mean value of 12.9 in cycle 1 to 11.1 g/dL in cycle 4, but no statistically significant difference was observed among or within the different arms. When groups A and D (long-term G-CSF) with groups B and C (short-term G-CSF) were compared, no statistically significant differences were seen in white blood cell, neutrophil, hemoglobin, or platelet counts. Univariate and multivariate analyses, comparing different age groups (under 50, 50 to 70, and under 70), nodal status (negative vs. positive), tumor size (<2 cm, 2.1 to 5 cm, and >5 cm), hormonal receptors, Her2-neu status, and tumor grade, did not show any statistically significant differences among or within groups for neutropenia, febrile neutropenia, or treatment delays.
We also estimated expenditures for G-CSF support for each group. A single dose of filgrastim (300 mcg) was rated at $243, resulting in a total cost per patient per cycle of $1944 for group A, $1215 for group B, and $972 for group C, whereas the cost of a single dose of pegfilgrastim (6 mg) was rated at $2608 for group D. The overall treatment cost of G-CSF per patient for all 4 cycles of chemotherapy in groups A, B, C, and D was $7776, $4860, $3888, and $10,432, respectively. These differences in costs did not include days of hospitalization or antibiotic treatment in patients with febrile neutropenia.
DISCUSSION
Randomized trials have shown high levels of leukocytosis after growth factor administration with the original 8-day schedule used at the CALGB trial, and with a single dose of pegfilgrastim on day 2. 15, 16 This suggests that shorter courses of filgrastrim may be sufficient for prophylaxis of neutropenia in the adjuvant treatment of patients with breast cancer receiving dose-dense chemotherapy. In our study, we did not find a statistically significant difference in the occurrence of febrile neutropenia and hospitalization events between pegfilgrastim or filgrastim given from days 3 to 10 as in the original CALGB study compared with shorter schedules of G-CSF (consecutively from days 3 to 7, or 4 times every other day on Group A: G-CSF 300 mcg days 3 to 10; group B: G-CSF 300 mcg days 3 to 7; group C: G-CSF 300 mcg days 5, 7, 9, and 11; group D: pegfilgrastim 6 mg day 2. BMI indicates body mass index; BSA, body surface area; FN, febrile neutropenia; G-CSF, granulocyte colony-stimulating factor. Group A: Granulocyte colony-stimulating factor (G-CSF) 300 mcg days 3 to 10; group B: G-CSF 300 mcg days 3 to 7; group C: G-CSF 300 mcg days 5, 7, 9, and 11; group D: pegfilgrastim 6 mg day 2.
days 5, 7, 9, and 11). There were fewer episodes of febrile neutropenia in the shortest-arm regimen (group C) of filgastrim administration, but no statistically significant difference was observed among the 4 groups or between long-term G-CSF treatment groups A and D versus short-term G-CSF groups B and C or groups A, B, and D versus group C. Nevertheless, when we compared group C (G-CSF days 5, 7, 9, and 11) with group D (pegfilgrastim), we found a statistically significant difference for the incidence of febrile neutropenia. Dose intensity was minimally compromised (3.0% treatment delays in groups B and C vs. 4.2% in groups A and D). The incidence of febrile neutropenia are higher in our study, 6%, compared with the overall incidence of febrile neutropenia observed in the CALGB 9741 study, 3%. 2 In comparison of the schedule used by CALGB 9741 (days 3 to 10), we also observed a higher rate of neutropenic fever (3.6% in group A of our study vs. 2% in arm 4 of the CALGB 9741 study). 2 We found a high incidence of febrile neutropenia in group D (pegfilgrastim, 10.5% of patients and 2.6% of cycles), which was surprisingly higher than the rate (1.5%) observed in a study of pegfilgrastim as hematopoietic support for dose-dense adjuvant chemotherapy in patients with breast cancer. 14 Importantly, 92% of the 135 women treated in that study received concomitant darbepoetin a, which may have contributed to the lower rate of febrile neutropenia. 20 In another study comparing the efficacy and safety profiles of pegfilgrastim and filgrastim in patients with breast cancer treated with 4 cycles of doxorubicin and docetaxel every 3 weeks as adjuvant chemotherapy, the rate of febrile neutropenia in the pegfilgrastim arm was 11%, similar to the incidence found in our study (10.5%). 21 Table 5 summarizes the incidence of febrile neutropenia in several studies comparing filgrastim and pegfilgrastim. In most studies, the rate of febrile neutropenia with the use of pegfilgrastim is approximately 10% as described by us.
The overall treatment cost per patient clearly indicated that the expenditure in groups B and C (short-term G-CSF) was approximately half ($4400) of that for groups A and D (longterm G-CSF and pegfilgrastim, $9100). Furthermore, as these less expensive schedules resulted in fewer episodes of febrile neutropenia and fewer hospitalization events, it might be assumed that the long-run overall savings were higher for these short-term G-SCF schedules. However, this saving is partially offset by an increase in costs when patients are given daily injections of filgrastim, requiring more nurses' working hours per patient. Regarding quality of life, it should be noted that patients prefer a single dose of pegfilgrastim (group D) rather than longer schedules of filgrastim (groups A, B and C) requiring more injections, and thus, potentially leading to more local pain and also being more time-consuming as patients have to come to the clinic for the administration of the drug.
The short-term use may reduce G-CSF-related bone pain and malaise. Both cost and quality-of-life issues should be further evaluated in prospective studies.
This was a single-institution, prospective, nonrandomized study in which the decision about the granulocyte growth factor support schedule was based on the primary physician's preference without consideration of patient variables or other parameters. All patients received the same chemotherapy regimen. The patients were well matched for other prognostic factors. Although our study is not randomized, the forced, unbiased circumstances of the growth-factor support selection justify a direct comparison among the 4 treatment groups.
The results of our study support the hypothesis that shorter filgrastim schedules in a dose-dense chemotherapy regimen in the adjuvant setting for high-risk patients with breast cancer is at least similar to longer schedules with regard to safety, incidence of febrile neutropenia, and hospitalization events. Furthermore, when we compared group C (G-CSF on days 5, 7, 9, and 11) with group D (pegfilgrastim), we found a statistically significant difference in the incidence of febrile neutropenia, with a substantial economic advantage favoring shorter G-CSF schedules compared with pegfilgrastim or longterm filgrastim schedules. Nevertheless, despite the nonrandom distribution of patients among the 4 treatment arms, and the clear imbalance in patient number per group, there was no statistically significant difference for known relevant variables among groups. A larger, prospective randomized trial should be done to evaluate shorter versus standard filgrastim and pegfilgrastim schedules, assessing differences in clinical outcomes, hematological and nonhematological toxicities, and direct and indirect impact on overall costs.
